| __timestamp | ACADIA Pharmaceuticals Inc. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 60602000 | 22732000 |
| Thursday, January 1, 2015 | 76369000 | 29245000 |
| Friday, January 1, 2016 | 4406000 | 33206000 |
| Sunday, January 1, 2017 | 13060000 | 31152000 |
| Monday, January 1, 2018 | 18330000 | 10136000 |
| Tuesday, January 1, 2019 | 19598000 | 45546000 |
| Wednesday, January 1, 2020 | 20550000 | 43367000 |
| Friday, January 1, 2021 | 19141000 | 81413000 |
| Saturday, January 1, 2022 | 10166000 | 139304000 |
| Sunday, January 1, 2023 | 45731000 | 192361000 |
| Monday, January 1, 2024 | 159417000 |
Infusing magic into the data realm
In the competitive landscape of biotechnology, understanding cost structures is crucial. This chart compares the cost of revenue for Halozyme Therapeutics, Inc. and ACADIA Pharmaceuticals Inc. from 2014 to 2023. Over this period, Halozyme's cost of revenue surged by approximately 747%, peaking in 2023. In contrast, ACADIA's costs fluctuated, with a notable 40% increase in 2023 compared to the previous year.
Halozyme's consistent growth in cost of revenue, especially the sharp rise in 2022 and 2023, suggests significant scaling or investment in production capabilities. Meanwhile, ACADIA's variable costs reflect strategic adjustments or market challenges. This data provides a window into the operational strategies of these companies, highlighting Halozyme's aggressive expansion and ACADIA's adaptive approach. Investors and industry analysts can glean insights into the financial health and strategic direction of these biotech firms through such cost analyses.
Novo Nordisk A/S vs Halozyme Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs Halozyme Therapeutics, Inc.
Cost Insights: Breaking Down Incyte Corporation and ACADIA Pharmaceuticals Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Bio-Techne Corporation vs Halozyme Therapeutics, Inc.
BioMarin Pharmaceutical Inc. vs ACADIA Pharmaceuticals Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and Halozyme Therapeutics, Inc.'s Expenses
Cost of Revenue: Key Insights for Sarepta Therapeutics, Inc. and ACADIA Pharmaceuticals Inc.
Analyzing Cost of Revenue: Halozyme Therapeutics, Inc. and Pharming Group N.V.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Mesoblast Limited's Expenses
Halozyme Therapeutics, Inc. vs Galapagos NV: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.
Cost of Revenue Trends: Grifols, S.A. vs ACADIA Pharmaceuticals Inc.